Savara’s (SVRA) “Buy” Rating Reiterated at HC Wainwright

Savara (NASDAQ:SVRA)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued on Friday,Benzinga reports. They currently have a $6.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 115.83% from the stock’s previous close.

A number of other research firms have also issued reports on SVRA. JMP Securities reissued a “market outperform” rating and issued a $9.00 price target on shares of Savara in a research report on Thursday, December 19th. Wells Fargo & Company assumed coverage on shares of Savara in a research note on Friday, December 20th. They set an “overweight” rating and a $8.00 target price for the company. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $8.83.

Savara Price Performance

Shares of NASDAQ:SVRA opened at $2.78 on Friday. The stock has a fifty day moving average of $2.72 and a 200-day moving average of $3.27. The company has a market capitalization of $477.10 million, a PE ratio of -6.47 and a beta of 0.60. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. Savara has a one year low of $2.26 and a one year high of $5.34.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). The company had revenue of $0.27 million for the quarter. As a group, equities analysts anticipate that Savara will post -0.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Savara

Several hedge funds have recently bought and sold shares of the business. Vestal Point Capital LP lifted its stake in shares of Savara by 33.2% in the fourth quarter. Vestal Point Capital LP now owns 10,775,000 shares of the company’s stock worth $33,079,000 after buying an additional 2,685,000 shares during the last quarter. Rosalind Advisors Inc. acquired a new stake in Savara in the 4th quarter worth $8,151,000. Nantahala Capital Management LLC raised its position in shares of Savara by 45.2% during the fourth quarter. Nantahala Capital Management LLC now owns 7,525,259 shares of the company’s stock valued at $23,103,000 after buying an additional 2,344,308 shares during the last quarter. Emerald Advisers LLC acquired a new position in Savara in the 4th quarter valued at approximately $7,161,000. Finally, Farallon Capital Management LLC increased its position in shares of Savara by 49.9% during the fourth quarter. Farallon Capital Management LLC now owns 6,835,000 shares of the company’s stock valued at $20,983,000 after purchasing an additional 2,275,000 shares during the period. 87.93% of the stock is owned by institutional investors and hedge funds.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.